Pharmacokinetic interaction of BCNU and misonidazole in humans.
Although considerable laboratory in vitro and in vivo evidence is now available suggesting that misonidazole (MISO) enhances chemotherapy tumor responses, experience with human tumors is limited. Further, the mechanism of this enhancement is not definitely known. One possible mechanism is that MISO alters the pharmacokinetics of the chemotherapeutic agent, vice versa or both. We studied a group of patients with recurrent malignant gliomas, following radiotherapy. After proven recurrence, they were treated with i.v. BCNU in combination with oral MISO in an 8 week cycle. Our aims were: 1. To obtain a second remission; 2. To assess the toxicity of this combination; 3. To assess the plasma pharmacokinetics of each drug alone and in combination. Six patients entered the protocol. Four of six patients obtained either a partial or subpartial response. Prolonged moderate myelosuppression was observed in 2/6 patients after 3 cycles; 2/6 patients experienced seizures after the first cycle of chemotherapy for the first time in the course of their disease. The plasma pharmacokinetic data indicates no evidence of a MISO-BCNU drug interaction.
D001855:Bone Marrow Diseases / Q000139:chemically induced; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008920:Misonidazole / Q000008:administration & dosage / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy; D009593:Nitroimidazoles / Q000494:pharmacology*
D009593:Nitroimidazoles; D008920:Misonidazole; D002330:Carmustine